Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Associates in Research Therapeutics of America LLC

Neither a doctor nor a teaching hospital

Research payments

$879,222

189 payments

Through program year 2025, Clinical Associates in Research Therapeutics of America LLC is reported as receiving $879,222 in research payments, across 189 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$197,307	22
2024	Research	$146,887	25
2023	Research	$142,689	23
2022	Research	$28,750	3
2021	Research	$162,659	53
2020	Research	$200,929	63

Breakdown

Who paid Research payments · program years 2020–2025

AbbVie, Inc. $424,449 126 payments
Pfizer Inc. $275,273 44 payments
F. Hoffmann-La Roche AG $120,175 11 payments
Genentech, Inc. $59,324 8 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy Safety and Tolerability of Ponsegromab in Patients With Cancer Cachexia and Elevated Concentrations of Gdf15 Followed By An Optional Openlabel Treatment Period $192,048 33 payments
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy $130,391 32 payments
CD P3: Double-Blind Induction $122,001 11 payments
M15-722 $118,767 22 payments
A Phase 1B Randomized Doubleblind Placebocontrolled Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Oral Pf07054894 in Adult Participants Aged 1875 Years With Moderate to Severe Ulcerative Colitis $83,225 11 payments
UC P3: Double-Blind Treat Straight Through $57,498 8 payments
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis $34,025 2 payments
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease $20,021 4 payments
M16-000 $16,836 12 payments
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease $16,597 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.